Case Report On Management and outcome of Cholangiocarcinoma

Pratiksha Palsapure1, Aparna Kawale2, Roshan Umate3, Pratiksha Munjewar4
1G.N.M. 3rd year, Florence Nightingale Training College of Nursing, Sawangi (M) Wardha
2Nursing Tutor, Florence Nightingale Training College of Nursing, Sawangi (M) Wardha
3Research Scientist, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra.
4Department of Medical-Surgical Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra.

Abstract

Cholangiocarcinoma refers to cancer of the bile duct. The bile tubes, which move digesting fluid through the liver, are cancerous. It's Cancer that's uncommon yet fatal. Cholangiocarcinoma of the bile duct is rarer; this bile duct cancer is typically discovered in the presence of obstructive jaundice. Cholangiocarcinoma patients usually have locally advanced disease at the time of diagnosis, with distant metastasis being uncommon.

The following are the key symptoms and/or clinical findings: Abdominal pain, fever, yellow skin and eyes (jaundice), and loss of appetite were the primary complaints of a 52-year-old elderly woman of was hospitalized at A.V.B.R. Hospital. A physical examination, a blood test, and a Colour Doppler test were all performed. The most common diagnoses, therapeutic interventions, and outcomes are as follows: Following a physical examination, investigation, blood tests, and a color doppler test, the patient was diagnosed with cholangiocarcinoma. Following his diagnosis, the patient was treated by Inj. Monocot IV, 1gm, 12 hourly. Inj. Pantoprazole IV, 40 mg, every 12 hours; Emset, 4 mg, every 8 hours, Tab. Udil 300 mg orally twice a day, Tab. Ultracet 50 mg twice a day, Inj. Vitamin k gave, Inj. Tramadol in 100 ml NS SOS, Syp. Duphalac 10 ml H.S., inj.Piptaz In addition, a patient filling has improved. Also conducted was "Percutaneous Transhepatic Biliary Drainage With Biliary Stenting." Cholangiocarcinoma, often known as bile duct cancer, is a rather uncommon condition. She responded well to all drugs and treatment, and she has made a wonderful recovery. Colangelo carcinoma is a phrase used to denote a form of cancer that affects the bile duct.

Keywords: cholangiocarcinoma, bile duct, cancer.

INTRODUCTION

Bile duct cancer and cholangiocarcinoma are frequently used interchangeably. Primary tract cancer affects one out of every 100,000 people die every year. Cholangiocarcinoma (epithelial adenocarcinomas) is the most common extrahepatic biliary tree cancer, accounting for about 95% of cases. In their fifth to seventh decades of life and men are significantly more likely than women to get this Cancer (1.3:1.0). What is Cholangiocarcinoma? Flowing from the common bile duct to the small intrahepatic bile ducts, small tumors can appear anywhere in the biliary system.

Cholangiocarcinoma is a cancerous tumor that develops from cells that resemble those seen in the bile duct epithelial cells. One or more solid, white cells form on the surface. Under the microscope, cholangiocarcinoma may resemble adenocarcinoma. Some of the tumors in the bile ductule are well-differentiated, whereas others are not.

Address for correspondence: Pratiksha Palsapure
G.N.M. 3rd year, Florence Nightingale Training College of Nursing, Sawangi (M) Wardha.
Email: pratiksha2809palsapure@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: pnrjournal@gmail.com

How to cite this article: Pratiksha Palsapure, Aparna Kawale, Roshan Umate, Pratiksha Munjewar, Case Report On Management and outcome of Cholangiocarcinoma, J PHARM NEGATIVE RESULTS 2022;13: 938-940.
When the D.N.A. of bile duct cells alters, cholangiocarcinoma develops. The changes promote uncontrollable cell growth, resulting in a mass of cells (tumor) that can invade and kill healthy body tissue. Cholangiocarcinoma might resemble adenocarcinoma under the microscope. Some bile duct tumors are highly distinguished, whereas others are not. Cholangiocarcinoma occurs when the D.N.A. of bile duct cells is altered. The modifications encourage uncontrolled cell development, leading to a mass of cells (tumor) that can infiltrate and damage healthy body tissue. Cholangiocarcinoma (bile duct cancer) is an uncommon type of bile duct cancer. It primarily affects the elderly, and by the time it is diagnosed, it has often progressed beyond the bile ducts. Cholangiocarcinoma is bile duct cancer. The most prevalent kind of bile duct cancer is adenocarcinoma. This growth begins in the mucus glands that coat the insides of the bile ducts. Cholangiocarcinoma (bile duct cancer) is an uncommon type of bile duct cancer. It is primarily a problem for the elderly. Extrahepatic (outside the liver) or intrahepatic (within the liver) bile duct tumors can occur (intrahepatic). Intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma are the two forms. The bile ducts within the liver are affected by intrahepatic cholangiocarcinoma, a kind of liver cancer. Hilar cholangiocarcinoma is seen in the bile ducts just outside the liver. Another name for this type is perihilar cholangiocarcinoma. The liver’s small duct branches are home to about 10% of bile duct cancer cases. Hepatocellular carcinoma, or primary liver cancer, is often confused with intrahepatic bile duct tumors. Most bile duct tumors develop outside of the liver, which is called extrahepatic cholangiocarcinoma. Extrahepatic bile duct carcinoma is the medical term for this. The hilum, which is where the left and right hepatic ducts exit the liver, is where about two-thirds of extrahepatic cancers form. About 90% of bile duct malignancies occur outside the liver, in a bile duct (extrahepatic). Cholangiocarcinomas are slow-growing cancers that invade other body systems through the lymphatic system. Long-term treatment and prognosis are based on the mass’s position. The prognosis of tumours in the middle or distal third of the extrahepatic bile duct, which make up around 45 percent of bile duct cancers (including Klatskin’s tumours — hilar variants), is better than that of tumours in the proximal Peripheral cholangiocarcinoma is characterised by large solitary tumours, but multinodular cholangiocarcinoma can sometimes happen. These tumours have weakly vascularized stroma that is fibrous, rigid, and greyish white in colour. Hilar cholangiocarcinoma is characterised by firm, intramural annular tumours that encircle the bile duct or by large, hard masses that extend into the liver from the duct or hilar region. They may also show up in the bile duct lumen as a spongy friable mass. There can be bile duct dilatation close to the mass and metastatic nodules all throughout the liver. Cholangiocarcinoma's clinical appearance is determined by the tumour’s anatomic location (s). The most common signs of hilar cholangiocarcinoma include jaundice, pruritis, abdominal pain, fever, weight loss, and/or weakness. (At the confluence of the right and left hepatic ducts, there is a tumor.) Patients with peripheral cholangiocarcinoma (tumor of the small intrahepatic ducts) may simply have vague abdominal pain, weight loss, weakness, and increased fatigue. Jaundice and pruritis may not manifest until later in the course of the disease when segmental bile ducts become blocked. Patients with distant cholangiocarcinoma (tumours of the extrahepatic bile ducts) commonly experience early onset of jaundice and pruritis without abdominal pain. On physical examination, these patients have a palpable enlarged gallbladder (Courvoisier’s sign). Cholangiocarcinoma has a poor prognosis and has a short life expectancy. We present the case of a patient who has lived an extraordinarily long time.

Patient Information:

On December 21, 2021, a female patient, 52, was admitted to A.V.B.R. Hospital with abdominal pain, fever, appetite loss, and yellow skin and eyes.

The primary concern and symptoms of the patient: The O.P.D. at A.V.B.R. hospital received a visit from a patient who was experiencing stomach pain, fever, loss of appetite, jaundice, and yellow skin and eyes. According to December 21, 2021, medical, family, and psycho-social history: There is currently no medical history to speak of. She was raised in a nuclear family with no one having any health issues. She was in good mental health and aware of the time, date, and location. Her interactions with family members and other patients have remained positive. She continued to have good relationships with the medical staff, the nurses, and the other patients.

Clinical finding: The patient was aware of the day, time, and location. She had an average physical look and kept up with her personal hygiene well. She was 57 kg in weight. Her vital signs indicate a fever, and her skin and eyes are yellow (jaundice) but generally normal. Her symptoms include fever, loss of appetite, jaundice, and yellow skin and eyes. According to December 21, 2021, diagnostic assessment: A blood test was done. Hemoglobin 9.3 gm, WBC Count of 19100 cu. mm, and Total R.B.C. Count 3.24 were all based on the patient's physical examination and medical history. Ultrasound was also performed in addition to the radiological test.

Diagnosis challenges: No diagnostic challenges were faced.

Diagnosis: Cholangiocarcinoma.

Prognosis: The patient's prognosis was good.

Therapeutic Intervention: Inj.Monocet 1gm IV 12 hourly, Inj.Pantoprazole 40 mg IV 12 hourly, Inj.Emset 4 mg 8 hourly, Tab.Udil 300 mg Iv BD, Tab.ultracet 50 mg BD, Inj.vitami k IV OD Inj.Tramadol in 100 mg N.S., S.O.S., Syp. Duphalac 10 ml H.S., inj. P "Percutaneous Transhepatic Biliary Drainage With Biliary Stenting" was performed as well.
Therapeutic Changes: No changes in medication and no any complication was seen inpatient. No any adverse effects of the drug on my patient.

Discussion:
Present case under physical examination and radiological investigation. This investigation was helpful for the early detection of diagnosis. According to the diagnosis, the patient got medical treatment in an emergency situation, and the patient life was secure.5-11

According to the literature that is now accessible, the incidence of tumours typically ranges from 0.7 percent to 11.7 percent, but in recent years, a progressive rise has been noticed, which may be attributed to the ageing population and developments in medical technology and equipment.12-20 According to estimates, 10% of cancer survivors in the US received at least one new primary cancer diagnosis between 1973 and 2000; this percentage has been increasing recently. In terms of the number of primary malignant tumours, MPM with two types of main malignant tumours is typical, whereas MPM with three or fewer types of primary malignant tumours is uncommon. The type, position, and extent of the blockage, the hilar lymph nodes, and other cholangiocarcinoma-related characteristics received more attention from medical professionals and imaging specialists than the stomach lesion did. Therefore, the patient's preoperative diagnosis of stomach cancer was negative.21-22

Conclusion:
Cholangiocarcinoma cancer this disease is rare. Early diagnosis and early treatment are necessary to prevent further complication. She was a response to all medication, and her recovery was good.

Conflict of Interest: No conflict of Interest
Funding: No Funding for case report